Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- AKRO
- Price
- 54.65
- Stock movement up
- +- (0.00%)
- Company name
- Akero Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 4.50B
- Ent value
- 4.37B
- Price/Sales
- 214748.36
- Price/Book
- 4.70
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 5.28%
- 1 year return
- 84.01%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-12-12
DIVIDENDS
AKRO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 214748.36 |
| Price to Book | 4.70 |
| EV to Sales | 214748.36 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 82.32M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | - |
| Gross profit (TTM) | - |
| Operating income (TTM) | - |
| Net income (TTM) | - |
| EPS (TTM) | - |
| EPS (1y forward) | -4.22 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 176.03M |
| Net receivables | 0.00 |
| Total current assets | 754.53M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 552.00K |
| Total assets | 1.01B |
| Accounts payable | 20.40M |
| Short/Current long term debt | 1.16M |
| Total current liabilities | 47.65M |
| Total liabilities | 47.94M |
| Shareholder's equity | 957.64M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | - |
| Capital expenditures (TTM) | - |
| Free cash flow (TTM) | - |
| Dividends paid (TTM) | - |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 54.52 |
| Daily high | 54.83 |
| Daily low | 54.42 |
| Daily Volume | 11.6M |
| All-time high | 57.56 |
| 1y analyst estimate | 56.50 |
| Beta | -0.40 |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 12 Mar 2026 |
Downside potential
Loading...
Downside potential data
| AKRO | S&P500 | |
| Current price drop from All-time high | -5.06% | -0.63% |
| Highest price drop | -61.55% | -19.00% |
| Date of highest drop | 14 Jan 2025 | 8 Apr 2025 |
| Avg drop from high | -23.72% | -2.57% |
| Avg time to new high | 293 days | 6 days |
| Max time to new high | 213 days | 89 days |
COMPANY DETAILS
Marketcap
4.50B
Marketcap category
Mid-cap
Description
Akero Therapeutics, Inc. engages in developing transformational treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Therapeutics, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. As of December 9, 2025, Akero Therapeutics, Inc. operates as a subsidiary of Novo Nordisk A/S.
Employees
74
Website
Investor relations
-
SEC filings
CEO
Andrew Cheng
Country
USA
City
South San Francisco
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner